Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Fleming

Vascular Surgery Sioux Falls, SD Medical Doctor

NPI 1841255932 CMS profile 310921

4520 W 69Th St, Sioux Falls, SD 57108

Open in the dashboard

General payments

$54,647

219 records reported · program years 2019–2025

Research payments

$2,813

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$78,957 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Mark Fleming of Sioux Falls, SD is reported in the CMS Open Payments database as having received $54,647 across 219 general payments and $2,813 in research payments paid to them. Separately, studies naming them as principal investigator received $78,957 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,002 56
2024 General $16,291 42
2023 General $3,071 30
2023 Research $188 1
2022 General $7,603 42
2021 General $3,787 26
2020 General $849 5
2020 Research $2,625 1
2019 General $12,045 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Fleming
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mark Fleming were reported at $11,002. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mark Fleming Vascular Surgery median Middle half National median
2019 $12,045 $796 $226–$2,363 $163
2020 $849 $348 $118–$1,110 $114
2021 $3,787 $471 $158–$1,421 $132
2022 $7,603 $725 $222–$2,183 $149
2023 $3,071 $836 $257–$2,440 $160
2024 $16,291 $909 $252–$2,619 $164
2025 $11,002 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $23,052 50 payments
  2. Medtronic, Inc. $18,628 81 payments
  3. Medtronic Vascular, Inc. $6,463 17 payments
  4. W. L. Gore & Associates, Inc. $3,268 22 payments
  5. Silk Road Medical, Inc. $959 11 payments
  6. Bard Peripheral Vascular, Inc. $366 3 payments
  7. Penumbra, Inc. $342 5 payments
  8. Abbott Laboratories $286 2 payments
  9. Cook Medical LLC $257 9 payments
  10. Shockwave Medical, Inc $168 4 payments
  11. Other $858 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,481 8 payments
  2. Travel and Lodging $14,167 30 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,563 4 payments
  4. Food and Beverage $10,437 177 payments
Products named General payments · program years 2019–2025
  1. General - Therapies $8,033 11 payments
  2. Abre $7,979 9 payments
  3. HawkOne Directional Atherectomy Devices $6,159 11 payments
  4. FlowMet $4,500 1 payment
  5. ANGIOJET $3,000 1 payment
  6. ELUVIA $3,000 1 payment
  7. GENERAL VASCULAR INTERVENTION $2,281 3 payments
  8. TurboHawk $2,078 19 payments
  9. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $2,071 11 payments
  10. HawkOne Directional Atherectomy Devices $1,184 18 payments
  11. Other $9,997 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $2,625 1 payment
  2. Medtronic, Inc. $188 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

311

Median for Vascular Surgery: 122

Drug cost

$55,768

Median for Vascular Surgery: $14,135

Branded share of claims

64.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 45 $33,386
Xarelto Rivaroxaban Brand 35 $20,293
Clopidogrel Clopidogrel Bisulfate Brand 120 $1,020
Atorvastatin Calcium Generic 61 $561
Rosuvastatin Calcium Generic 50 $509

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 164 billing codes

Paid by Medicare

$246,442

Medicare's payments for the services billed

Medicare patients

891

Average age 75

Services billed

2,624

431 women, 460 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 45%
Diabetes 41%
Chronic kidney disease 41%
Heart failure 30%
Atrial fibrillation 29%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record